Post Translational Medicines (PTM) is unlocking the dark proteome by mapping and targeting proteoforms—the diverse, functional states of proteins shaped by post-translational modifications and conformational changes. Powered by its proprietary Surveyor™ platform, PTM integrates next-generation proteomics and AI to systematically reveal hidden disease mechanisms and develop first-in-class therapies for cancer and age-related diseases.